Sequential Use of Romiplostim after Eltrombopag for Refractory Thrombocytopenia in Hydrocarbon-Induced Myelodysplasia

Abstract

We describe the clinical course of a 65-year-old male patient who suffered from hydrocarbon-induced myelodysplasia and was successfully treated with the thrombopoietin receptor agonist (TPO-RA), romiplostim. Myelodysplastic syndromes (MDS) are characterized by ineffective hematopoiesis, cytopenias, and increased risk of leukemic transformation. Here, we present a clinical vignette of MDS-associated thrombocytopenia refractory to first-line drugs as well as the TPO-RA, eltrombopag. To date, romiplostim is an U.S. Food and Drug Administration (FDA)-approved drug for idiopathic thrombocytopenic purpura and thrombocytopenia secondary to liver disease. Of note, currently the FDA advises against its use in MDS based on previous long-term safety concerns. Since the therapeutic options for thrombocytopenia in MDS patients are sparse, repurposing and reassessing romiplostim in this setting have been the focus of recent studies. At the time of writing, no published double-blind randomized clinical trials have conducted a head-to-head comparison between romiplostim and eltrombopag in thrombocytopenic MDS patients. To the best of our knowledge, for a thrombocytopenic patient in the setting of MDS, this is the first documented report of refractory clinical response after a 2-year use of eltrombopag in which replacement of treatment with romiplostim resulted in sustained physiological counts of thrombocytes within four weeks.

Keywords

romiplostim - myelodysplastic syndromes - thrombopoietin receptor agonist - thrombopoiesis - thrombocytopenia - eltrombopag

^* These authors had equal contribution.

Publication History

Received: 27 August 2020

Accepted: 19 January 2021

Article published online:
03 September 2021

• References

• 1 Will B, Zhou L, Vogler TO. et al. Stem and progenitor cells in myelodysplastic syndromes show aberrant stage-specific expansion and harbor genetic and epigenetic alterations. Blood 2012; 120 (10) 2076-2086
• 2 Pang WW, Pluvinage JV, Price EA. et al. Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes. Proc Natl Acad Sci U S A 2013; 110 (08) 3011-3016
• 3 Cazzola M. Myelodysplastic syndromes. N Engl J Med 2020; 383 (14) 1358-1374
• 4 Dayyani F, Conley AP, Strom SS. et al. Cause of death in patients with lower-risk myelodysplastic syndrome. Cancer 2010; 116 (09) 2174-2179
• 5 Schnatter AR, Glass DC, Tang G, Irons RD, Rushton L. Myelodysplastic syndrome and benzene exposure among petroleum workers: an international pooled analysis. J Natl Cancer Inst 2012; 104 (22) 1724-1737
• 6 Rushton L, Schnatter AR, Tang G, Glass DC. Acute myeloid and chronic lymphoid leukaemias and exposure to low-level benzene among petroleum workers. Br J Cancer 2014; 110 (03) 783-787
• 7 Verma DK, des Tombe K. Benzene in gasoline and crude oil: occupational and environmental implications. AIHA J (Fairfax, Va) 2002; 63 (02) 225-230
• 8 Loomis D, Guyton KZ, Grosse Y. et al; International Agency for Research on Cancer Monograph Working Group. Carcinogenicity of benzene. Lancet Oncol 2017; 18 (12) 1574-1575
• 9 Mason LH, Harp JP, Han DY. Pb neurotoxicity: neuropsychological effects of lead toxicity. BioMed Res Int 2014; 2014: 840547
• 10 Le QH, Tran DD, Chen YC, Nguyen HL. Risk of lead exposure from transport stations to human health: a case study in the highland province of Vietnam. Toxics 2019; 7 (03) 48
• 11 Aoki T, Harada Y, Matsubara E. et al. Thrombopoietin receptor agonists in refractory immune thrombocytopenia: differential responses to eltrombopag and romiplostim: a case report and possible explanations. J Clin Pharm Ther 2012; 37 (06) 729-732
• 12 González-Porras JR, Mingot-Castellano ME, Andrade MM. et al. Use of eltrombopag after romiplostim in primary immune thrombocytopenia. Br J Haematol 2015; 169 (01) 111-116
• 13 Piccin A, Amaddii G, Natolino F, Billio A, Cortelazzo S. Idiopathic thrombocytopenic purpura resistant to eltrombopag, but cured with romiplostim. Blood Transfus 2014; 12 (1, suppl 1): s149-s150
• 14 Kuter DJ, Bussel JB, Lyons RM. et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet 2008; 371 (9610): 395-403
• 15 Zhang J, Liang Y, Ai Y. et al. Eltrombopag versus romiplostim in treatment of adult patients with immune thrombocytopenia: a systematic review incorporating an indirect-comparison meta-analysis. PLoS One 2018; 13 (06) e0198504
• 16 Bussel JB, Buchanan GR, Nugent DJ. et al. A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia. Blood 2011; 118 (01) 28-36
• 17 Moussa MM, Mowafy N. Preoperative use of romiplostim in thrombocytopenic patients with chronic hepatitis C and liver cirrhosis. J Gastroenterol Hepatol 2013; 28 (02) 335-341
• 18 Afdhal NH, Dusheiko GM, Giannini EG. et al. Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy. Gastroenterology 2014; 146 (02) 442-52.e1
• 19 Dusheiko G, Afdhal NH, Giannini E. et al. Final results of open-label treatment with eltrombopag during ENABLE 1: a study of eltrombopag as an adjunct for antiviral treatment of hepatitis C virus associated with thrombocytopenia. . Hepatology 2011
• 20 Solar GP, Kerr WG, Zeigler FC. et al. Role of c-mpl in early hematopoiesis. Blood 1998; 92 (01) 4-10
• 21 Debili N, Wendling F, Cosman D. et al. The Mpl receptor is expressed in the megakaryocytic lineage from late progenitors to platelets. Blood 1995; 85 (02) 391-401
• 22 Kantarjian H, O'Brien S, Ravandi F. et al. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer 2008; 113 (06) 1351-1361
• 23 Kantarjian H, Giles F, List A. et al. The incidence and impact of thrombocytopenia in myelodysplastic syndromes. Cancer 2007; 109 (09) 1705-1714
• 24 Hofmann WK, Koeffler HP. Myelodysplastic syndrome. Annu Rev Med 2005; 56: 1-16
• 25 D'Arena G, Guariglia R, Mansueto G. et al. No cross-resistance after sequential use of romiplostim and eltrombopag in chronic immune thrombocytopenic purpura. [published correction appears in Blood. 2014 Mar 20;123(12):1971. Dosage error in article text] Blood 2013; 121 (07) 1240-1242
• 26 Rusnak DW, Rudolph SK, Safavi A, Erickson-Miller CL. Eltrombopag, but not romiplostim or thrombopoietin, inhibits growth of thrombopoietin receptor positive and negative human leukemia cell lines. Blood 2012; 120 (02) 386-394
• 27 Stasi R, Evangelista ML, Amadori S. Novel thrombopoietic agents: a review of their use in idiopathic thrombocytopenic purpura. Drugs 2008; 68 (07) 901-912
• 28 Raslova H, Vainchenker W, Plo I. Eltrombopag, a potent stimulator of megakaryopoiesis. Haematologica 2016; 101 (12) 1443-1445
• 29 Giagounidis A, Mufti GJ, Fenaux P. et al. Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1-risk myelodysplastic syndrome and thrombocytopenia. Cancer 2014; 120 (12) 1838-1846